Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 477

1.

Functional Characterization of a GGPPS Variant Identified in Atypical Femoral Fracture Patients and Delineation of the Role of GGPPS in Bone-Relevant Cell Types.

Roca-Ayats N, Ng PY, Garcia-Giralt N, Falcó-Mascaró M, Cozar M, Abril JF, Quesada Gómez JM, Prieto-Alhambra D, Nogués X, Dunford JE, Russell RG, Baron R, Grinberg D, Balcells S, Díez-Pérez A.

J Bone Miner Res. 2018 Sep 5. doi: 10.1002/jbmr.3580. [Epub ahead of print]

PMID:
30184270
2.

GGPS1 Mutation and Atypical Femoral Fractures with Bisphosphonates.

Roca-Ayats N, Balcells S, Garcia-Giralt N, Falcó-Mascaró M, Martínez-Gil N, Abril JF, Urreizti R, Dopazo J, Quesada-Gómez JM, Nogués X, Mellibovsky L, Prieto-Alhambra D, Dunford JE, Javaid MK, Russell RG, Grinberg D, Díez-Pérez A.

N Engl J Med. 2017 May 4;376(18):1794-1795. doi: 10.1056/NEJMc1612804. No abstract available.

3.

The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate).

Lawson MA, Ebetino FH, Mazur A, Chantry AD, Paton-Hough J, Evans HR, Lath D, Tsoumpra MK, Lundy MW, Dobson RL, Quijano M, Kwaasi AA, Dunford JE, Duan X, Triffitt JT, Jeans G, Russell RGG.

J Bone Miner Res. 2017 Sep;32(9):1860-1869. doi: 10.1002/jbmr.3138. Epub 2017 Apr 21.

4.

Competency milestones for medical students: Design, implementation, and analysis at one medical school.

Lomis KD, Russell RG, Davidson MA, Fleming AE, Pettepher CC, Cutrer WB, Fleming GM, Miller BM.

Med Teach. 2017 May;39(5):494-504. doi: 10.1080/0142159X.2017.1299924. Epub 2017 Mar 10.

PMID:
28281837
5.

Design, Synthesis, and Antimicrobial Evaluation of a Novel Bone-Targeting Bisphosphonate-Ciprofloxacin Conjugate for the Treatment of Osteomyelitis Biofilms.

Sedghizadeh PP, Sun S, Junka AF, Richard E, Sadrerafi K, Mahabady S, Bakhshalian N, Tjokro N, Bartoszewicz M, Oleksy M, Szymczyk P, Lundy MW, Neighbors JD, Russell RG, McKenna CE, Ebetino FH.

J Med Chem. 2017 Mar 23;60(6):2326-2343. doi: 10.1021/acs.jmedchem.6b01615. Epub 2017 Feb 13.

6.

How do we understand the determinants of health? An exploration of distributed knowledge and interprofessional health sciences education.

Russell RG, Davidson H, Rhoads C, Petrusa ER.

J Interprof Care. 2017 Jan;31(1):118-121. Epub 2016 Nov 16.

PMID:
27849415
7.

Pyrophosphate: a key inhibitor of mineralisation.

Orriss IR, Arnett TR, Russell RG.

Curr Opin Pharmacol. 2016 Jun;28:57-68. doi: 10.1016/j.coph.2016.03.003. Epub 2016 Apr 7. Review.

PMID:
27061894
8.

Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their Function.

Misra J, Mohanty ST, Madan S, Fernandes JA, Hal Ebetino F, Russell RG, Bellantuono I.

Stem Cells. 2016 Mar;34(3):756-67. doi: 10.1002/stem.2255. Epub 2015 Dec 22.

9.

Fluorescent Bisphosphonate and Carboxyphosphonate Probes: A Versatile Imaging Toolkit for Applications in Bone Biology and Biomedicine.

Sun S, Błażewska KM, Kadina AP, Kashemirov BA, Duan X, Triffitt JT, Dunford JE, Russell RG, Ebetino FH, Roelofs AJ, Coxon FP, Lundy MW, McKenna CE.

Bioconjug Chem. 2016 Feb 17;27(2):329-40. doi: 10.1021/acs.bioconjchem.5b00369. Epub 2015 Dec 8.

10.

The inhibition of human farnesyl pyrophosphate synthase by nitrogen-containing bisphosphonates. Elucidating the role of active site threonine 201 and tyrosine 204 residues using enzyme mutants.

Tsoumpra MK, Muniz JR, Barnett BL, Kwaasi AA, Pilka ES, Kavanagh KL, Evdokimov A, Walter RL, Von Delft F, Ebetino FH, Oppermann U, Russell RGG, Dunford JE.

Bone. 2015 Dec;81:478-486. doi: 10.1016/j.bone.2015.08.020. Epub 2015 Aug 28.

11.

Pharmacological diversity among drugs that inhibit bone resorption.

Russell RG.

Curr Opin Pharmacol. 2015 Jun;22:115-30. doi: 10.1016/j.coph.2015.05.005. Epub 2015 Jun 3. Review.

PMID:
26048735
12.

Editorial overview: Musculoskeletal: Are there common targets to prevent age-related changes in muscle, cartilage and bone?

Gallagher JA, Russell RG.

Curr Opin Pharmacol. 2015 Jun;22:v-viii. doi: 10.1016/j.coph.2015.05.007. Epub 2015 May 29. No abstract available.

PMID:
26031883
13.

Tribute to Stephen M. Krane.

Dayer JM, Goldring MB, Goldring SR, Kronenberg HM, Martin TJ, Russell RG.

J Bone Miner Res. 2015 May;30(5):751-2. doi: 10.1002/jbmr.2477. No abstract available.

14.

A critical role of acute bronchoconstriction in the mortality associated with high-dose sarin inhalation: effects of epinephrine and oxygen therapies.

Gundavarapu S, Zhuang J, Barrett EG, Xu F, Russell RG, Sopori ML.

Toxicol Appl Pharmacol. 2014 Jan 15;274(2):200-8. doi: 10.1016/j.taap.2013.11.007. Epub 2013 Nov 19.

PMID:
24269878
15.

Eliminating the need for fasting with oral administration of bisphosphonates.

Pazianas M, Abrahamsen B, Ferrari S, Russell RG.

Ther Clin Risk Manag. 2013;9:395-402. doi: 10.2147/TCRM.S52291. Epub 2013 Oct 18.

16.

Findings of Danish study on risk of colon cancer in bisphosphonate users were misinterpreted.

Abrahamsen B, Pazianas M, Russell RG.

BMJ. 2013 Mar 12;346:f1514. doi: 10.1136/bmj.f1514. No abstract available.

PMID:
23482976
17.

Evaluation of potential for toxicity from subacute inhalation of tire and road wear particles in rats.

Kreider ML, Doyle-Eisele M, Russell RG, McDonald JD, Panko JM.

Inhal Toxicol. 2012 Nov;24(13):907-17. doi: 10.3109/08958378.2012.730071.

PMID:
23121300
18.

FPIN's Clinical Inquiries. Treatment of motion sickness.

Sutton M, Mounsey AL, Russell RG.

Am Fam Physician. 2012 Jul 15;86(2):192-5. Review. No abstract available.

19.

Bisphosphonates and colon cancer: reply.

Pazianas M, Abrahamsen B, Eiken PA, Eastell R, Russell RG.

Osteoporos Int. 2013 Mar;24(3):1141-2. doi: 10.1007/s00198-012-2079-6. Epub 2012 Jul 31. No abstract available.

PMID:
22847317
20.

Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.

Pazianas M, Abrahamsen B, Wang Y, Russell RG.

Osteoporos Int. 2012 Dec;23(12):2873-84. doi: 10.1007/s00198-012-1952-7. Epub 2012 Mar 20.

PMID:
22431012
21.

Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study.

Pazianas M, Abrahamsen B, Eiken PA, Eastell R, Russell RG.

Osteoporos Int. 2012 Nov;23(11):2693-701. doi: 10.1007/s00198-012-1902-4. Epub 2012 Mar 6.

PMID:
22392160
22.

Potential therapeutic effects of oral bisphosphonates on the intestine.

Pazianas M, Russell RG.

Ann N Y Acad Sci. 2011 Dec;1240:E19-25. doi: 10.1111/j.1749-6632.2011.06372.x. Review.

PMID:
22360293
23.

Bisphosphonate binding affinity affects drug distribution in both intracortical and trabecular bone of rabbits.

Turek J, Ebetino FH, Lundy MW, Sun S, Kashemirov BA, McKenna CE, Gallant MA, Plotkin LI, Bellido T, Duan X, Triffitt JT, Russell RG, Burr DB, Allen MR.

Calcif Tissue Int. 2012 Mar;90(3):202-10. doi: 10.1007/s00223-012-9570-0. Epub 2012 Jan 17.

PMID:
22249525
24.

Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo.

Roelofs AJ, Stewart CA, Sun S, Błażewska KM, Kashemirov BA, McKenna CE, Russell RG, Rogers MJ, Lundy MW, Ebetino FH, Coxon FP.

J Bone Miner Res. 2012 Apr;27(4):835-47. doi: 10.1002/jbmr.1543.

25.

From nuclear physics to bone cell biology--Maureen Owen--1927-2011.

Triffitt JT, Russell RG.

Bone. 2011 Dec;49(6):1121-4. No abstract available.

PMID:
22206099
26.

Esophageal and gastric cancer incidence and mortality in alendronate users.

Abrahamsen B, Pazianas M, Eiken P, Russell RG, Eastell R.

J Bone Miner Res. 2012 Mar;27(3):679-86. doi: 10.1002/jbmr.1481.

27.

Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.

Bradbury LA, Barlow S, Geoghegan F, Hannon RA, Stuckey SL, Wass JA, Russell RG, Brown MA, Duncan EL.

Osteoporos Int. 2012 Jan;23(1):285-94. doi: 10.1007/s00198-011-1658-2. Epub 2011 Jul 8.

PMID:
21739105
28.

If you don't take it - it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy.

Adachi JD, Josse RG, Russell RG.

Ther Clin Risk Manag. 2011;7:181-98. doi: 10.2147/TCRM.S17513. Epub 2011 May 24.

29.

Bisphosphonates: the first 40 years.

Russell RG.

Bone. 2011 Jul;49(1):2-19. doi: 10.1016/j.bone.2011.04.022. Epub 2011 May 1. Review.

PMID:
21555003
30.

Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice.

Sugiyama T, Meakin LB, Galea GL, Jackson BF, Lanyon LE, Ebetino FH, Russell RG, Price JS.

Bone. 2011 Jul;49(1):133-9. doi: 10.1016/j.bone.2011.03.775. Epub 2011 Apr 9.

31.

The relationship between the chemistry and biological activity of the bisphosphonates.

Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG.

Bone. 2011 Jul;49(1):20-33. doi: 10.1016/j.bone.2011.03.774. Epub 2011 Apr 9. Review.

PMID:
21497677
32.

Atrial fibrillation and the use of oral bisphosphonates.

Pazianas M, Cooper C, Wang Y, Lange JL, Russell RG.

Ther Clin Risk Manag. 2011;7:131-44. doi: 10.2147/TCRM.S17899. Epub 2011 Mar 22.

33.

Denosumab and bisphosphonates: different mechanisms of action and effects.

Baron R, Ferrari S, Russell RG.

Bone. 2011 Apr 1;48(4):677-92. doi: 10.1016/j.bone.2010.11.020. Epub 2010 Dec 9. Review.

PMID:
21145999
34.

Molecular characterization of a novel geranylgeranyl pyrophosphate synthase from Plasmodium parasites.

Artz JD, Wernimont AK, Dunford JE, Schapira M, Dong A, Zhao Y, Lew J, Russell RG, Ebetino FH, Oppermann U, Hui R.

J Biol Chem. 2011 Feb 4;286(5):3315-22. doi: 10.1074/jbc.M109.027235. Epub 2010 Nov 17.

35.

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.

Pazianas M, Cooper C, Ebetino FH, Russell RG.

Ther Clin Risk Manag. 2010 Jul 21;6:325-43.

36.

2009 Santa Fe Bone symposium.

Lewiecki EM, Bilezikian JP, Laster AJ, Miller PD, Recker RR, Russell RGG, Whyte MP.

J Clin Densitom. 2010 Jan-Mar;13(1):1-9. doi: 10.1016/j.jocd.2009.12.003. Review.

PMID:
20171564
37.

Differences between bisphosphonates in binding affinities for hydroxyapatite.

Lawson MA, Xia Z, Barnett BL, Triffitt JT, Phipps RJ, Dunford JE, Locklin RM, Ebetino FH, Russell RG.

J Biomed Mater Res B Appl Biomater. 2010 Jan;92(1):149-55. doi: 10.1002/jbm.b.31500.

PMID:
19904734
38.

Safety of oral sulfates in rats and dogs contrasted with phosphate-induced nephropathy in rats.

Pelham RW, Russell RG, Padgett EL, Reno FE, Cleveland Mv.

Int J Toxicol. 2009 Mar-Apr;28(2):99-112. doi: 10.1177/1091581809335124.

PMID:
19482834
39.

Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patients.

Petrie KA, Lee WH, Bullock AN, Pointon JJ, Smith R, Russell RG, Brown MA, Wordsworth BP, Triffitt JT.

PLoS One. 2009;4(3):e5005. doi: 10.1371/journal.pone.0005005. Epub 2009 Mar 30.

40.

Prolonged osteogenesis from human mesenchymal stem cells implanted in immunodeficient mice by using coralline hydroxyapatite incorporating rhBMP2 microspheres.

Fu K, Xu Q, Czernuszka J, McKenna CE, Ebetino FH, Russell RG, Triffitt JT, Xia Z.

J Biomed Mater Res A. 2010 Mar 15;92(4):1256-64. doi: 10.1002/jbm.a.32453.

PMID:
19322875
41.

Targeting a uniquely nonspecific prenyl synthase with bisphosphonates to combat cryptosporidiosis.

Artz JD, Dunford JE, Arrowood MJ, Dong A, Chruszcz M, Kavanagh KL, Minor W, Russell RG, Ebetino FH, Oppermann U, Hui R.

Chem Biol. 2008 Dec 22;15(12):1296-306. doi: 10.1016/j.chembiol.2008.10.017.

42.

Osteonecrosis of the jaw: more heat than light.

Pazianas M, Russell RG, Fogelman I.

J Nucl Med. 2009 Jan;50(1):6-7. doi: 10.2967/jnumed.108.057885. Epub 2008 Dec 17. No abstract available.

43.

Fluorescently labeled risedronate and related analogues: "magic linker" synthesis.

Kashemirov BA, Bala JL, Chen X, Ebetino FH, Xia Z, Russell RG, Coxon FP, Roelofs AJ, Rogers MJ, McKenna CE.

Bioconjug Chem. 2008 Dec;19(12):2308-10. doi: 10.1021/bc800369c.

PMID:
19032080
44.

Does regular exercise reduce the pain and stiffness of osteoarthritis?

Blackham J, Garry JP, Cummings DM, Russell RG, Dealleaume L.

J Fam Pract. 2008 Jul;57(7):476-7. Review.

PMID:
18625172
45.

Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.

Dunford JE, Kwaasi AA, Rogers MJ, Barnett BL, Ebetino FH, Russell RG, Oppermann U, Kavanagh KL.

J Med Chem. 2008 Apr 10;51(7):2187-95. doi: 10.1021/jm7015733. Epub 2008 Mar 8.

PMID:
18327899
46.

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

Russell RG, Watts NB, Ebetino FH, Rogers MJ.

Osteoporos Int. 2008 Jun;19(6):733-59. doi: 10.1007/s00198-007-0540-8. Review.

PMID:
18214569
47.

Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.

Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3219-28. Epub 2007 Dec 7.

48.

Regulation of bim in glucocorticoid-mediated osteoblast apoptosis.

Espina B, Liang M, Russell RG, Hulley PA.

J Cell Physiol. 2008 May;215(2):488-96.

49.

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.

Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH.

Ann N Y Acad Sci. 2007 Nov;1117:209-57. Review.

PMID:
18056045
50.

Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate.

Marma MS, Xia Z, Stewart C, Coxon F, Dunford JE, Baron R, Kashemirov BA, Ebetino FH, Triffitt JT, Russell RG, McKenna CE.

J Med Chem. 2007 Nov 29;50(24):5967-75. Epub 2007 Nov 2.

PMID:
17975902

Supplemental Content

Loading ...
Support Center